See more : Port of Tauranga Limited (PTAUF) Income Statement Analysis – Financial Results
Complete financial analysis of Global Cord Blood Corporation (CO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Global Cord Blood Corporation, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- The First Bank Of Toyama, Ltd. (7184.T) Income Statement Analysis – Financial Results
- Canadian Utilities Limited (CDUUF) Income Statement Analysis – Financial Results
- Apollo Strategic Growth Capital (APSG) Income Statement Analysis – Financial Results
- The Tochigi Bank, Ltd. (8550.T) Income Statement Analysis – Financial Results
- Rural Funds Group (RFF.AX) Income Statement Analysis – Financial Results
Global Cord Blood Corporation (CO)
Industry: Medical - Diagnostics & Research
Sector: Healthcare
Website: https://www.globalcordbloodcorp.com
About Global Cord Blood Corporation
Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.24B | 1.16B | 1.22B | 986.75M | 936.77M | 759.98M | 663.00M | 635.12M | 572.86M | 526.12M | 380.49M | 339.53M | 261.54M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 183.31M | 178.95M | 189.13M | 186.03M | 181.48M | 142.64M | 144.60M | 130.61M | 106.23M | 106.62M | 86.66M | 77.38M | 65.73M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.06B | 980.69M | 1.03B | 800.73M | 755.29M | 617.34M | 518.40M | 504.51M | 466.63M | 419.50M | 293.83M | 262.16M | 195.81M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 85.26% | 84.57% | 84.52% | 81.15% | 80.63% | 81.23% | 78.19% | 79.44% | 81.46% | 79.73% | 77.22% | 77.21% | 74.87% | 0.00% | 0.00% | 0.00% |
| Research & Development | 22.30M | 23.77M | 21.11M | 14.69M | 12.72M | 10.37M | 8.96M | 9.91M | 9.77M | 8.46M | 7.62M | 6.96M | 5.82M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 187.06M | 174.36M | 190.23M | 169.32M | 243.50M | 189.94M | 169.95M | 131.68M | 112.24M | 108.05M | 89.70M | 83.79M | 53.32M | 11.20M | 0.00 | 0.00 |
| Selling & Marketing | 241.73M | 237.69M | 261.96M | 235.06M | 219.20M | 178.48M | 148.16M | 127.93M | 112.69M | 93.68M | 61.68M | 47.58M | 39.48M | 0.00 | 0.00 | 0.00 |
| SG&A | 428.79M | 412.05M | 452.19M | 404.38M | 462.70M | 368.42M | 318.11M | 259.61M | 224.93M | 201.73M | 151.37M | 131.38M | 92.80M | 11.20M | 4.01M | 66.28K |
| Other Expenses | 6.27M | 8.16M | 7.39M | 5.70M | 4.23M | 5.97M | -113.00K | 861.00K | 2.21M | 203.00K | 0.00 | 0.00 | 0.00 | 594.98K | 220.52K | 166.41K |
| Operating Expenses | 451.08M | 435.82M | 473.30M | 419.07M | 475.42M | 352.47M | 327.07M | 269.52M | 234.71M | 210.19M | 158.99M | 138.34M | 98.61M | 11.80M | 4.23M | 232.69K |
| Cost & Expenses | 634.39M | 614.77M | 662.43M | 605.10M | 656.91M | 495.11M | 471.67M | 400.13M | 340.93M | 316.81M | 245.65M | 215.71M | 164.34M | 11.80M | 4.23M | 232.69K |
| Interest Income | 32.61M | 30.90M | 25.36M | 25.32M | 21.94M | 17.42M | 18.22M | 18.25M | 16.87M | 15.06M | 13.43M | 9.07M | 6.41M | 4.11M | 0.00 | 250.79K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 3.26M | 119.42M | 107.97M | 101.10M | 70.08M | 70.10M | 3.29M | 2.61M | 2.43M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 19.91M | -26.82M | 12.97M | 52.37M | 50.59M | 50.48M | 50.17M | 50.61M | 37.07M | 35.87M | 29.36M | 23.48M | 20.43M | 3.92M | 7.10M | 250.79K |
| EBITDA | 628.78M | 518.05M | 572.00M | 404.75M | 353.60M | 333.71M | 299.10M | 306.33M | 297.44M | 256.96M | 174.26M | 151.71M | 96.81M | -7.88M | 2.87M | 18.11K |
| EBITDA Ratio | 50.58% | 44.67% | 46.83% | 41.02% | 37.75% | 43.91% | 45.11% | 48.23% | 51.92% | 48.84% | 45.80% | 44.68% | 37.02% | 0.00% | 0.00% | 0.00% |
| Operating Income | 608.87M | 544.87M | 559.03M | 381.66M | 279.86M | 264.87M | 191.33M | 235.00M | 231.93M | 209.31M | 134.84M | 123.82M | 97.19M | -11.80M | -4.23M | -232.69K |
| Operating Income Ratio | 48.97% | 46.99% | 45.77% | 38.68% | 29.88% | 34.85% | 28.86% | 37.00% | 40.49% | 39.78% | 35.44% | 36.47% | 37.16% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 18.97M | 65.88M | 19.78M | -25.20M | 23.67M | -98.55M | -50.00M | -79.88M | -41.00M | -51.13M | 16.76M | 8.32M | -17.53M | 3.92M | 7.10M | 250.79K |
| Income Before Tax | 627.84M | 610.75M | 578.81M | 356.46M | 303.54M | 166.31M | 141.33M | 155.12M | 190.92M | 158.19M | 151.60M | 132.14M | 79.66M | -7.88M | 2.87M | 18.11K |
| Income Before Tax Ratio | 50.50% | 52.67% | 47.39% | 36.12% | 32.40% | 21.88% | 21.32% | 24.42% | 33.33% | 30.07% | 39.84% | 38.92% | 30.46% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 118.35M | 94.55M | 101.08M | 61.26M | 62.66M | 37.62M | 50.00M | 47.33M | 58.40M | 38.54M | 9.63M | 33.93M | 24.77M | -4.11M | -7.47M | -18.11K |
| Net Income | 501.07M | 508.25M | 470.72M | 291.12M | 237.10M | 126.19M | 90.97M | 107.29M | 131.90M | 112.45M | 131.98M | 91.70M | 49.18M | -7.88M | 2.87M | 18.11K |
| Net Income Ratio | 40.30% | 43.83% | 38.54% | 29.50% | 25.31% | 16.60% | 13.72% | 16.89% | 23.03% | 21.37% | 34.69% | 27.01% | 18.80% | 0.00% | 0.00% | 0.00% |
| EPS | 4.12 | 4.18 | 3.87 | 2.40 | 1.99 | 1.59 | 1.25 | 1.36 | 1.60 | 1.49 | 1.79 | 1.31 | 0.69 | -1.13 | 0.41 | 0.01 |
| EPS Diluted | 4.12 | 4.18 | 3.87 | 2.40 | 1.99 | 1.59 | 1.25 | 1.36 | 1.60 | 1.49 | 1.79 | 1.31 | 0.66 | -1.13 | 0.41 | 0.01 |
| Weighted Avg Shares Out | 121.55M | 121.55M | 121.55M | 121.30M | 119.14M | 79.36M | 72.78M | 78.89M | 82.44M | 75.47M | 73.73M | 70.00M | 71.27M | 7.00M | 7.00M | 1.49M |
| Weighted Avg Shares Out (Dil) | 121.55M | 121.55M | 121.55M | 121.30M | 119.14M | 79.36M | 72.78M | 78.89M | 82.44M | 75.47M | 73.73M | 70.00M | 74.51M | 7.00M | 7.00M | 1.49M |
Kirby McInerney LLP Reminds Global Cord Blood Corporation (CORBF) Investors of Upcoming Deadline in Class Action Filing
NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of...
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Global Cord
NEW YORK , May 31, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Global Cord Blood Corporation ("Global Cord" or the "Company") (NYSE: CO, OTC: CORBF) and reminds investors of...
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Global Cord Blood Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - CO, CORBF
NEW YORK , May 30, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Global Cord Blood Corporation (NYSE: CO) (OTC: CORBF) between June 4, 2019 and May 3, 2022, both...
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Global Cord Blood Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - CO, CORBF
NEW YORK , May 20, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Global Cord Blood Corporation (NYSE: CO) (OTC: CORBF) between June 4, 2019 and May 3, 2022, both dates...
ROSEN, A TOP RANKED LAW FIRM, Encourages Global Cord Blood Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - CO, CORBF
ROSEN, A TOP RANKED LAW FIRM, Encourages Global Cord Blood Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - CO, CORBF May 19, 2024 4:52 PM EDT | Source: The Rosen Law Firm PA New York,...
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Global Cord Blood Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - CO, CORBF
NEW YORK , May 13, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Global Cord Blood Corporation (NYSE: CO) (OTC: CORBF) between June 4, 2019 and May 3, 2022, both dates...
CO Stockholders with Significant Losses Should Contact Robbins LLP for Information About the Global Cord Blood Corporation Securities Class Action
SAN DIEGO--(BUSINESS WIRE)---- $CO #CO--Robbins LLP is Investigating the Allegations that the Board of Global Cord Blood Corporation (CO) Engaged in Self-Serving and Conflicted Transactions.
ROSEN, A LEADING LAW FIRM, Encourages Global Cord Blood Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - CO, CORBF
NEW YORK , May 6, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Global Cord Blood Corporation (NYSE: CO) (OTC: CORBF) between June 4, 2019 and May 3, 2022, both...
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Global Cord
NEW YORK , May 3, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Global Cord Blood Corporation ("Global Cord" or the "Company") (NYSE: CO, OTC: CORBF) and reminds investors of...
ROSEN, A RANKED AND LEADING FIRM, Encourages Global Cord Blood Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - CO, CORBF
NEW YORK, April 26, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Global Cord Blood Corporation (NYSE: CO) (OTC: CORBF)...
Source: https://incomestatements.info
Category: Stock Reports